$1.13 EPS Expected for Eli Lilly and Company (LLY)

April 23, 2018 - By Clifton Ray

Eli Lilly and Company (NYSE:LLY) LogoInvestors sentiment increased to 1.1 in Q4 2017. Its up 0.21, from 0.89 in 2017Q3. It increased, as 42 investors sold Eli Lilly and Company shares while 380 reduced holdings. 117 funds opened positions while 346 raised stakes. 827.08 million shares or 0.09% less from 827.83 million shares in 2017Q3 were reported.
Chesapeake Asset Mgmt Limited Liability Com holds 24,405 shares. Arizona State Retirement reported 0.23% stake. Schulhoff Co Incorporated invested in 0.44% or 9,250 shares. Quantitative Mgmt Ltd owns 124,800 shares or 0.16% of their US portfolio. Capital Intll Ca has invested 0.21% in Eli Lilly and Company (NYSE:LLY). 10,440 are held by Brookstone Mgmt. Mason Street Advsr Lc holds 0.26% or 134,956 shares. 16,373 were reported by Fayez Sarofim And. Jacobs And Comm Ca holds 0.67% or 43,927 shares in its portfolio. Bedrijfstakpensioenfonds Voor De Media Pno holds 98,000 shares. Investec Asset Management Ltd stated it has 0.67% in Eli Lilly and Company (NYSE:LLY). Ftb Advsr holds 5,688 shares or 0.05% of its portfolio. Appleton Prtn Ma has 0.09% invested in Eli Lilly and Company (NYSE:LLY) for 6,896 shares. Evercore Wealth Mgmt Ltd Liability Corp has invested 0.08% in Eli Lilly and Company (NYSE:LLY). Gulf Commercial Bank (Uk) invested in 0.34% or 312,786 shares.

Since December 11, 2017, it had 0 insider purchases, and 8 selling transactions for $21.75 million activity. $17.64 million worth of Eli Lilly and Company (NYSE:LLY) was sold by LILLY ENDOWMENT INC on Wednesday, December 13. 3,000 shares valued at $237,600 were sold by Smiley Joshua L on Friday, March 16. Another trade for 12,500 shares valued at $1.08 million was made by Simmons Jeffrey N on Monday, December 11. $1.81 million worth of Eli Lilly and Company (NYSE:LLY) shares were sold by Mahony Susan.

Analysts expect Eli Lilly and Company (NYSE:LLY) to report $1.13 EPS on April, 24 before the open.They anticipate $0.15 EPS change or 15.31 % from last quarter’s $0.98 EPS. LLY’s profit would be $1.18B giving it 17.49 P/E if the $1.13 EPS is correct. After having $1.14 EPS previously, Eli Lilly and Company’s analysts see -0.88 % EPS growth. The stock decreased 0.87% or $0.69 during the last trading session, reaching $79.06. About 5.42M shares traded or 9.01% up from the average. Eli Lilly and Company (NYSE:LLY) has declined 10.19% since April 23, 2017 and is downtrending. It has underperformed by 21.74% the S&P500.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

Among 11 analysts covering Eli Lilly & Co (NYSE:LLY), 5 have Buy rating, 1 Sell and 5 Hold. Therefore 45% are positive. Eli Lilly & Co had 19 analyst reports since October 27, 2017 according to SRatingsIntel. Jefferies maintained the shares of LLY in report on Friday, March 23 with “Buy” rating. The firm has “Buy” rating by Jefferies given on Thursday, November 16. The stock of Eli Lilly and Company (NYSE:LLY) earned “Buy” rating by Jefferies on Friday, April 13. As per Wednesday, December 13, the company rating was maintained by Leerink Swann. SunTrust maintained it with “Buy” rating and $101.0 target in Friday, October 27 report. BMO Capital Markets maintained Eli Lilly and Company (NYSE:LLY) on Monday, November 13 with “Sell” rating. The firm has “Equal-Weight” rating given on Tuesday, November 21 by Morgan Stanley. The stock of Eli Lilly and Company (NYSE:LLY) earned “Hold” rating by Goldman Sachs on Tuesday, January 16. Jefferies maintained the shares of LLY in report on Monday, February 26 with “Buy” rating. BMO Capital Markets upgraded the shares of LLY in report on Friday, April 13 to “Market Perform” rating.

Eli Lilly and Company discovers, develops, makes, and markets pharmaceutical products worldwide. The company has market cap of $82.38 billion. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products. It currently has negative earnings. The firm offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.

Eli Lilly and Company (NYSE:LLY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.